Can circulating miR-7-1-5p, and miR-33a-5p be used as markers of T2D patients?
Biomarker
Type-2 diabetes
miR-33a-5p
miR-7-5p
microRNAs
Journal
Archives of physiology and biochemistry
ISSN: 1744-4160
Titre abrégé: Arch Physiol Biochem
Pays: England
ID NLM: 9510153
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
10
5
2023
pubmed:
22
1
2021
entrez:
21
1
2021
Statut:
ppublish
Résumé
Recent evidence has indicated that miRNAs play an important role in both initiation and progression of many pathologic processes such as diabetes and can be used as an important and more sensitive tool to predict the development of the disease than the currently used biomarkers. This research aimed at comparing miR-7-5p and miR-33a-5p expression levels in the diabetics and pre-diabetics with the control group. In this study, we compared expression of miR-7-5p and miR-33a-5p in plasma of three groups including pre-diabetic patients ( Compared to the controls, miR-7-1-5p expression was down regulated in the pre-diabetics and the T2D patients; whereas, miR-33a-5p was expressed at higher levels in the T2D patients compared to the control group. Both miRs were correlated with glycaemic status such as FBS and HbA1c levels. The ROC analysis indicated a significant ability for miR-33a-5p in discriminating between the diabetics and the healthy individuals. Our results demonstrated that the miR-7-1-5p and miR-33a-5p expression levels are deregulated in the diabetics and pre-diabetics. Furthermore, miR-33a-5p showed significant ability in discriminating between diabetics and healthy individuals, suggesting a potential diagnostic use of miRNAs in type-2 diabetes detection.
Identifiants
pubmed: 33476198
doi: 10.1080/13813455.2021.1871762
doi:
Substances chimiques
MicroRNAs
0
Biomarkers
0
Insulin
0
MIRN7 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM